Search results
Takeda Pharmaceutical: A Long-Term Cash Cow
GuruFocus.com via Yahoo Finance· 2 days agoTakeda Pharmaceutical Co. Ltd. (NYSE:TAK) is the largest Japanese pharmaceutical company and holds a leading position in the global immunoglobulins...
Takeda To Add Mid-Stage Autoimmune Disease Candidate For $4B
Benzinga via Yahoo Finance· 1 year agoTakeda Pharmaceutical Co Ltd (NYSE: TAK) will acquire NDI-034858 from Nimbus Therapeutics, an oral,...
Takeda's Approved Blood Cancer Drug Hits Primary Goal In Newly-Diagnosed Patient Settings
Benzinga via Yahoo Finance· 1 year agoTakeda Pharmaceutical Co Ltd's (NYSE: TAK) Phase 3 PhALLCON trial of Iclusig (ponatinib) met its...
Takeda Reports 13% Fall In Nine Month Operating Profit, Keeps Annual Guidance Unchanged
Benzinga via Yahoo Finance· 1 year agoTakeda Pharmaceutical Co Ltd (NYSE: TAK) reported a 13% drop in operating earnings to ¥401.9 billion...
Takeda's FY22 Net Profit Jumps 38%, But Expects Lower FY23 Revenues
Benzinga via Yahoo Finance· 12 months agoTakeda Pharmaceutical Co Ltd's (NYSE: TAK) FY22 net profit rose 37.8% to ¥317.02 billion, mainly due...
Takeda's Highest Dose Psoriasis Candidate Can Potentially Beat Bristol Myers' Approved Drug, Analyst...
Benzinga via Yahoo Finance· 1 year agoTakeda Pharmaceutical Co Ltd (NYSE: TAK) announced results from a Phase 2b clinical trial of TAK-279...
Takeda Posts Lower 1H Profit, Lifts FY22 Outlook
Benzinga via Yahoo Finance· 1 year agoTakeda Pharmaceutical Co Ltd's (NYSE: TAK) first-half net profit declined 9.2% from the prior year to ¥166.8 billion. Earnings per share fell 8.1% to...
Arrowhead Pharmaceuticals Reports Underwhelming Data From Inherited Disease Study
Benzinga via Yahoo Finance· 1 year agoTakeda Pharmaceutical Co Ltd (NYSE: TAK) and Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) announced...
Takeda Presents Vedolizumab Data For Preventing Graft-Versus-Host Disease In Stem Cell Transplant...
Benzinga via Yahoo Finance· 1 year agoTakeda Pharmaceutical Co Ltd (NYSE: TAK) announced late-breaking data from the Phase 3 GRAPHITE...
Takeda Moves Out From Licensing Agreement With Theravance Biopharma
Benzinga via Yahoo Finance· 11 months agoIn its Q1 earnings release, Takeda Pharmaceutical Co Ltd (NYSE: TAK) said it agreed to discontinue...